To gain physician trust, AI companies must move beyond proving their algorithm is accurate. The gold standard is large-scale clinical evidence demonstrating tangible improvements in patient outcomes, treatment rates, and decision-making speed.
For critical care AI tools, the key to adoption is not just accuracy but seamless integration. A "zero-click" approach that automatically processes scans and delivers results without adding steps to a clinician's workflow is paramount for buy-in.
Instead of focusing only on physicians, Brainomix positions its AI as a value-add for the entire stroke treatment ecosystem. By helping increase the use of existing drugs and devices, they create strategic alignment with powerful pharma and med device partners.
A MedTech startup's initial go-to-market may be hospital-by-hospital sales. However, after building a robust evidence base of clinical and economic impact, the sales focus can shift to enterprise-level deals with regional or national healthcare systems, accelerating growth.
The transition from academia to entrepreneurship is most successful when the focus shifts from pure science or technology to solving a tangible, pre-existing clinical problem. This ensures market interest, clinical adoption, and ultimately, patient impact from the outset.
A successful MedTech platform can be a blueprint for expansion. By identifying new disease areas with similar core problems (e.g., imaging-based diagnosis delays), a company can replicate its proven strategies for product development, evidence generation, and partnerships.
A common clinical need doesn't mean a one-size-fits-all commercial strategy. To scale globally, companies must appreciate the technical, clinical, and commercial differences in each healthcare system and invest in local resources to navigate them successfully.